HS
Himmat Sunder Lal Lodha
About Himmat Sunder Lal Lodha
Data last updated:
Himmat Sunder Lal Lodha is a Cfo at Bilakhia Holdings Private Limited (since 2022), Director at Mexus Corporation Private Limited (since 2022) and Director at M3 Investment Private Limited (since 2024), and holds 10 more current directorships. The companies operate in Financial Services, Real Estate and Construction and Life Sciences. The 5 current companies with reported revenue have a combined latest revenue of ₹3,691 Cr; the largest is Bilakhia Holdings Private Limited at ₹3,664 Cr (FY 2024). Earlier, Himmat Sunder Lal Lodha was an Additional Director at Moyal Investment Private Limited (2016) and Director at Midas Specialty Private Limited (from 2012) and 9 more.
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Bilakhia Holdings Private Limited U67120GJ1992PTC017523 | Cfo | 01 Jul 2022 | 1992 | ₹3,664 Cr (FY 2024) | Active |
 Mexus Corporation Private Limited U45201GJ1999PTC036443 | Director | 01 Apr 2022 | 1999 | ₹12.51 Cr (FY 2025) | Active |
| M3 Investment Private Limited U65993GJ2005PTC045417 | Director | 08 Feb 2024 | 2005 | ₹11.86 Cr (FY 2019) | Active |
 Micro Crispr Private Limited U33309GJ2021PTC124575 | Director | 02 Aug 2021 | 2021 | ₹3.08 Cr (FY 2025) | Active |
| Nuvo Labs Private Limited U62099GJ2023PTC143047 | Director | 18 Jul 2023 | 2023 | ₹43,000 (FY 2025) | Active |
| Micro Cell Therapies Private Limited U21009GJ2026PTC181509 | Non- Individual Subscriber | 29 Jul 2026 | 2026 | Active | |
| Merai Accelerators Private Limited U62099GJ2024PTC150825 | Director | 22 Apr 2024 | 2024 | Active | |
| Nuvo Ai Private Limited U62099GJ2023PTC142003 | Director | 09 Jun 2023 | 2023 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Moyal Investment Private Limited U65993GJ2009PTC058459 | Additional Director | 01 Aug 2016 | 2009 | ₹5.95 Cr (FY 2025) | Active |
| Midas Specialty Private Limited U15499GJ2002PTC040964 | Director | 15 Jun 2012 | 2002 | Strike Off | |
| Meril Pharmaceuticals Private Limited U24100GJ2011PTC065363 | Director | 10 Feb 2015 | 2011 | Strike Off | |
| Hindustan Inks Private Limited U24110GJ2005PTC045414 | Director | 15 Jun 2012 | 2005 | Strike Off | |
| Meril Therapeutics Private Limited U33110GJ2011PTC065364 | Director | 10 Feb 2015 | 2011 | Strike Off | |
| Meril Ophthalmic Private Limited U33110GJ2011PTC066547 | Director | 10 Feb 2015 | 2011 | Strike Off | |
| Meril Dental Private Limited U33110GJ2011PTC068200 | Director | 10 Feb 2015 | 2011 | Strike Off | |
| Meril Ent Private Limited U33110GJ2011PTC068202 | Director | 10 Feb 2015 | 2011 | Strike Off | |
| Meril Imaging Private Limited U33110GJ2011PTC068204 | Director | 10 Feb 2015 | 2011 | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Himmat Sunder Lal Lodha
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Himmat Sunder Lal Lodha
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Himmat Sunder Lal Lodha
Himmat Sunder Lal Lodha currently holds 13 directorships: Bilakhia Holdings Private Limited (Cfo, since 01 Jul 2022, revenue ₹3,664 Cr (FY 2024)); Mexus Corporation Private Limited (Director, since 01 Apr 2022, revenue ₹12.51 Cr (FY 2025)); M3 Investment Private Limited (Director, since 08 Feb 2024, revenue ₹11.86 Cr (FY 2019)); Micro Crispr Private Limited (Director, since 02 Aug 2021, revenue ₹3.08 Cr (FY 2025)); Nuvo Labs Private Limited (Director, since 18 Jul 2023, revenue ₹43,000 (FY 2025)); and 8 more.
Himmat Sunder Lal Lodha was first appointed on 25 Feb 2012 as Director at M3 Investment Managers Private Limited. The most recent appointment on record is 29 Jul 2026 at Micro Cell Therapies Private Limited.
The 5 current companies of Himmat Sunder Lal Lodha that report revenue have a combined latest revenue of ₹3,691 Cr: Bilakhia Holdings Private Limited ₹3,664 Cr (FY 2024); Mexus Corporation Private Limited ₹12.51 Cr (FY 2025); M3 Investment Private Limited ₹11.86 Cr (FY 2019); Micro Crispr Private Limited ₹3.08 Cr (FY 2025); Nuvo Labs Private Limited ₹43,000 (FY 2025).
Himmat Sunder Lal Lodha held 11 earlier board appointments: Moyal Investment Private Limited (Additional Director, 01 Aug 2016 to 22 Aug 2016); Midas Specialty Private Limited (Director, from 15 Jun 2012); Meril Pharmaceuticals Private Limited (Director, from 10 Feb 2015); Hindustan Inks Private Limited (Director, from 15 Jun 2012); Meril Therapeutics Private Limited (Director, from 10 Feb 2015); and 6 more.
The current boards of Himmat Sunder Lal Lodha's companies include Anjum Gafulbhai Bilakhia (Bilakhia Holdings Private Limited), Jakir Gafulbhai Bilakhia (Bilakhia Holdings Private Limited), Lekhendra Nath Chaturvedi (Bilakhia Holdings Private Limited), Navinchandra Paragji Patel (Bilakhia Holdings Private Limited), Udit Kamalchandra Kothari (Bilakhia Holdings Private Limited), Yunus Gafulbhai Bilakhia (Bilakhia Holdings Private Limited), among others.